SGHT
Sight Sciences, Inc.·Healthcare
3.45
1.429%(−0.05)
Market ClosedLast Updated: — ET
52W L: $2.3052W H: $9.24
SGHT NEWS
defenseworld.net
5d ago
Insider Selling: Sight Sciences (NASDAQ:SGHT) EVP Sells $10,615.30 in Stock
Sight Sciences, Inc. (NASDAQ: SGHT - Get Free Report) EVP Brenton Taylor sold 2,869 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $3.70, for a total value of $10,615.30. Following the completion of the sale, the executive vice president directly owned 267,807
defenseworld.net
5d ago
Sight Sciences (NASDAQ:SGHT) CTO Sells $28,424.64 in Stock
Sight Sciences, Inc. (NASDAQ: SGHT - Get Free Report) CTO David Badawi sold 8,168 shares of Sight Sciences stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.48, for a total transaction of $28,424.64. Following the transaction, the chief technology officer directly owned 1,990,290 shares in
defenseworld.net
6d ago
Paul Badawi Sells 29,244 Shares of Sight Sciences (NASDAQ:SGHT) Stock
Sight Sciences, Inc. (NASDAQ: SGHT - Get Free Report) CEO Paul Badawi sold 29,244 shares of Sight Sciences stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $3.70, for a total value of $108,202.80. Following the sale, the chief executive officer directly owned 6,151,156 shares in the company,
globenewswire.com
Apr 1
Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that data on two of its proprietary glaucoma and dry eye technologies, the OMNI® Surgical System and the TearCare® System, will be presented at this year's ASCRS Annual Meeting held in Washington, DC.
globenewswire.com
Mar 30
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the 25th Annual Needham Healthcare Conference being held virtually.
globenewswire.com
Mar 30
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
Court preserves jury's finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 Court preserves jury's finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028
